Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aceto To Acquire Selected Assets Of Andrews Paper & Chemical
Andrews Paper & Chemical is a supplier of diazos and couplers to the paper, film, and electronics industries. Specific end uses for its products include microfilm, whiteprint (“blueprints”
Andrews Paper & Chemical is a supplier of diazos and couplers to the paper, film, and electronics industries. Specific end uses for its products include microfilm, whiteprint (“blueprints”
Reportedly, the products have been marketed by Pfizer and Wyeth’s Fort Dodge operations. Elanco also expected to acquire a manufacturing facility in Sligo, Ireland, currently used in the
CINtec Plus will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via
Nanotechnologies have been proven as a valuable adjunct to the development of new therapeutics. Nanoparticles provide a much larger surface area thereby increasing the dissolution rate resulting in
Through a separate process, the EU Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC. IMGN901 is an
Insys said that all primary and secondary endpoints were achieved in the study, and the drug has demonstrated pain relief when measuring the summary of pain intensity difference
Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure. Abbott Point of Care’s i-STAT System, a handheld diagnostic
WuXi PharmaTech posted a net income of $12.13m, compared to net loss of $93.85m for the comparable period in 2008. Operating income was $13.58m, compared to operating loss
As per the agreement, Nabi will be entitled to receive an upfront payment of $40m and GSK will be granted an option to exclusively in-license NicVAX on a
Reportedly, the entreprise value of Merial has been fixed at $8bn and the entreprise value of Intervet/Schering-Plough at $8.5bn, leading to a true-up payment of $250m to Merck